Ando, K.; Manabe, R.; Kishino, Y.; Kusumoto, S.; Yamaoka, T.; Tanaka, A.; Ohmori, T.; Ohnishi, T.; Sagara, H.
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis. Cancers 2021, 13, 52.
https://doi.org/10.3390/cancers13010052
AMA Style
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H.
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis. Cancers. 2021; 13(1):52.
https://doi.org/10.3390/cancers13010052
Chicago/Turabian Style
Ando, Koichi, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, and Hironori Sagara.
2021. "Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis" Cancers 13, no. 1: 52.
https://doi.org/10.3390/cancers13010052
APA Style
Ando, K., Manabe, R., Kishino, Y., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., Ohnishi, T., & Sagara, H.
(2021). Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis. Cancers, 13(1), 52.
https://doi.org/10.3390/cancers13010052